COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Prospective Assessment of the Efficacy of Hyaluronate Knee Injections in Patients With Osteoarthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00323778
Recruitment Status : Terminated
First Posted : May 10, 2006
Last Update Posted : February 6, 2008
Information provided by:
Hospital for Special Surgery, New York

Brief Summary:
This study looks at the effect of an injectable medication called Hyalgan on the cartilage of the knee in people who have osteoarthritis ("wear and tear arthritis") of the knee. Hyalgan is a medication which is injected into the knee, and is FDA approved to treat knee arthritis. We will be using magnetic resonance imaging (MRI) and x-rays to look at knee cartilage to see how it responds over the course of a year to the injections. A comparison to patients taking oral pain medication will be made.

Condition or disease Intervention/treatment Phase
Knee Osteoarthritis Drug: Hyalgan Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: Prospective Assessment of the Efficacy of Intra-Articular Hyaluronate to Affect Extracellular Matrix Changes in Patients With Osteoarthritis
Study Start Date : May 2006
Actual Primary Completion Date : September 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   45 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age 45-90
  • seeking medical care for painful knee osteoarthritis
  • alignment based on AP standing radiographs of neutral to 10º of valgus
  • no prior surgery on the ipsilateral knee
  • no history of major trauma to either knee or either hip
  • no history of congenital hip dysplasia
  • No history of inflammatory synovitis or crystalline arthropathy
  • No history of systemic rheumatic disease
  • cruciate and collateral ligament stability, defined by clinical examination
  • meniscus intact (MRI grade II degenerative signal acceptable)
  • Noyes compartment score: no greater than 50% of cartilage thickness over an area greater than 15mm
  • If bilateral OA, the most painful knee, (as documented by VAS scale for pain) which qualifies for the study will be entered.
  • If taking glucosamine chondroitin sulfate, discontinue at least one month prior to HA injections

Exclusion Criteria:

  • previous IA HA injection in the ipsilateral knee
  • IA steroid in the ipsilateral knee in the past 3 months
  • MR evidence of inflammatory or hypertrophic synovitis
  • Large joint effusion with a ballotable patella on baseline clinical exam
  • Inability to safely perform MR imaging
  • Active systemic infection
  • Active malignancy (except non-melanomatous skin cancer)
  • Allergies to HA or chicken products
  • Clinical symptoms of an acute meniscal tear (locking, new acute mechanical symptoms etc…)
  • A recent injury to the knee
  • Radiographic evidence of Grade III or IV Kellgren and Lawrence OA
  • Chondrocalcinosis on radiographs
  • Unwilling to discontinue or avoid glucosamine chondroitin sulfate for the 12 month study period
  • People taking blood thinners or who have bleeding problems
  • Anticipated lower extremity surgery during the next 12 months
  • BMI >30 kg/m2

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00323778

Layout table for location information
United States, New York
Hospital for Special Surgery
New York, New York, United States, 10021
Sponsors and Collaborators
Hospital for Special Surgery, New York
Layout table for investigator information
Principal Investigator: Lisa A Mandl, MD MPH Hospital for Special Surgery, New York
Layout table for additonal information
Responsible Party: Lisa A. Mandl MD MPH, Hospital for Special Surgery Identifier: NCT00323778    
Other Study ID Numbers: 25107
First Posted: May 10, 2006    Key Record Dates
Last Update Posted: February 6, 2008
Last Verified: February 2008
Keywords provided by Hospital for Special Surgery, New York:
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis, Knee
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Hyaluronic Acid
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Protective Agents